Methods for diagnosing prostate cancer and predicting prostate cancer relapse

US10760132B2 · kind B2 · utility

Assignee

• University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventors

• Jianhua Luo · Wexford, US
• George Konstantine Michalopoulos · Pittsburgh, US
• Joel B. Nelson · Pittsburgh, US
• Chi Song · New Haven, US
• Chien-Cheng Tseng · Pittsburgh, US
• Yanping Yu · Wexford, US

Key dates

• Filing date: Jul 21, 2014
• Grant date: Sep 1, 2020
• Expiry date: Jul 21, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.